The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
HIV protease inhibitors: a review of molecular selectivity and toxicity
Open accessAbstract
Highly active antiretroviral therapy (HAART) is recognized as the most effective treatment method for AIDS, and protease inhibitors play a very important role in HAART. However, poor bioavailability and unbearable toxicity are their common disadvantages. Thus, the development of safer and potentially promising protease inhibitors is eagerly needed. In this review, we introduced the chemical characteristics and associated side effects of HIV protease inhibitors, as well as the possible off-target mechanisms causing the side effects. From the chemical structures of HIV protease inhibitors and their possible off-target molecules, we could obtain hints for optimizing the molecular selectivity of the inhibitors, to provide help in the design of new compounds with enhanced bioavailability and reduced side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Endoplasmic Reticulum Stress Triggers Autophagy
Yorimitsu, T., Nair, U., Yang, Z., & Klionsky, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607007200 · Cited by 951
Kim, J. B., Sarraf, P., Wright, M., Yao, K. M., Mueller, E., Solanes, G., Lowell, B. B., & Spiegelman, B. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1411 · Cited by 792
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074609 · Cited by 680
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022048 · Cited by 625
The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy
Murata, H., Hruz, P. W., & Mueckler, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000228200 · Cited by 586
Mulligan, K., Grunfeld, C., Tai, V. W., Algren, H., Pang, M., Chernoff, D. N., Lo, J. C., & Schambelan, M. (2000) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200001010-00005 · Cited by 518
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3218 · Cited by 471
Fajas, L., Schoonjans, K., Gelman, L., Kim, J. B., Najib, J., Martin, G., Fruchart, J.-C., Briggs, M., Spiegelman, B. M., & Auwerx, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5495 · Cited by 444
Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.654 · Cited by 417
Sakai, J., Rawson, R. B., Espenshade, P. J., Cheng, D., Seegmiller, A. C., Goldstein, J. L., & Brown, M. S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80150-1 · Cited by 405
Bastard, J.-P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P.-M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08094-7 · Cited by 405
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
Purnell, J. Q., Zambon, A., Knopp, R. H., Pizzuti, D. J., Achari, R., Leonard, J. M., Locke, C., & Brunzell, J. D. (2000) · AIDS · doi:10.1097/00002030-200001070-00006 · Cited by 387
Eron, J., Yeni, P., Gathe, J., Estrada, V., DeJesus, E., Staszewski, S., Lackey, P., Katlama, C., Young, B., Yau, L., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69155-1 · Cited by 344
Gills, J. J., LoPiccolo, J., Tsurutani, J., Shoemaker, R. H., Best, C. J. M., Abu-Asab, M. S., Borojerdi, J., Warfel, N. A., Gardner, E. R., Danish, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0161 · Cited by 320
Zeldin, R. K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh029 · Cited by 316
Caron, M., Auclair, M., Vigouroux, C., Glorian, M., Forest, C., & Capeau, J. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1378 · Cited by 313
André, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., & Lotteau, V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13120 · Cited by 279
Indinavir-associated lipodystrophy
Viraben, R., & Aquilina, C. (1998) · AIDS · doi:10.1097/00002030-199806000-00001 · Cited by 271
Liang, J.-S., Distler, O., Cooper, D. A., Jamil, H., Deckelbaum, R. J., Ginsberg, H. N., & Sturley, S. L. (2001) · Nature Medicine · doi:10.1038/nm1201-1327 · Cited by 261
Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations
Murata, H., Hruz, P. W., & Mueckler, M. (2002) · AIDS · doi:10.1097/00002030-200204120-00005 · Cited by 251
Krohn, A., Redshaw, S., Ritchie, J. C., Graves, B. J., & Hatada, M. H. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00115a028 · Cited by 233
Lipoproteins and the pathogenesis of atherosclerosis.
Steinberg, D. H., Carew, T. E., Fielding, C., Fogelman, A. M., Mahley, R. W., Sniderman, A. D., & Zilversmit, D. B. (1989) · Circulation · doi:10.1161/01.cir.80.3.719 · Cited by 227
Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
Paton, N. I., Kityo, C., Hoppe, A., Reid, A., Kambugu, A., Lugemwa, A., van Oosterhout, J. J., Kiconco, M., Siika, A., Mwebaze, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311274 · Cited by 202
Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence
Max, B., & Sherer, R. (2000) · Clinical Infectious Diseases · doi:10.1086/313859 · Cited by 201
Sato, R., Yang, J., Wang, X., Evans, M. J., Ho, Y. K., Goldstein, J. L., & Brown, M. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32550-4 · Cited by 197
Noor, M. A., Parker, R. A., O'Mara, E., Grasela, D. M., Currie, A., Hodder, S. L., Fiedorek, F. T., & Haas, D. W. (2004) · AIDS · doi:10.1097/00002030-200411050-00005 · Cited by 197
Murphy, R. L., Sanne, I., Cahn, P., Phanuphak, P., Percival, L., Kelleher, T., & Giordano, M. (2003) · AIDS · doi:10.1097/00002030-200312050-00007 · Cited by 195
Ritonavir and saquinavir combination therapy for the treatment of HIV infection
Cameron, W., Japour, A. J., Xu, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., et al. (1999) · AIDS · doi:10.1097/00002030-199902040-00009 · Cited by 191
Pajonk, F., Himmelsbach, J., Riess, K., Sommer, A. H., & McBride, W. H. (2002) · PubMed · Cited by 190
Hirano, Y., Yoshida, M., Shimizu, M., & Sato, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105200200 · Cited by 151
Wang, X., Pai, J., Wiedenfeld, E. A., Medina, J. C., Slaughter, C. A., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.18044 · Cited by 138
Kotler, D. P. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318186519c · Cited by 129
Xu, A., Yin, S., Wong, L. S. L., Chan, K. W., & Lam, K. S. L. (2003) · Endocrinology · doi:10.1210/en.2003-1140 · Cited by 120
Dauchy, F., Lawson‐Ayayi, S., de la Faille, R., Bonnet, F., Rigothier, C., Mehsen, N., Miremont‐Salamé, G., Cazanave, C., Greib, C., Dabis, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.124 · Cited by 115
Cameron, D. W., da Silva, B. A., Arribas, J. R., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/589622 · Cited by 111
Inhibition of HIV‐2 Protease by HIV‐1 Protease Inhibitors in Clinical Use
Brower, E. T., Bacha, U., Kawasaki, Y., & Freire, E. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00647.x · Cited by 109
Parker, R. A., Flint, O. P., Mulvey, R., Elosua, C., Wang, F., Fenderson, W., Wang, S., Yang, W.-P., & Noor, M. A. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010165 · Cited by 105
Zhou, H., Gurley, E. C., Brimson, S., Ding, H., Fang, Y., Xu, Z., Pandak, W. M., & Hylemon, P. B. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00182.2006 · Cited by 100
Metabolic Complications Associated with HIV Protease Inhibitor Therapy
Nolan, D. A. (2003) · Drugs · doi:10.2165/00003495-200363230-00001 · Cited by 98
A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity
Hertel, J., Struthers, H., Horj, C. B., & Hruz, P. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410826200 · Cited by 91
Rusconi, S., Catamancio, S. L. S., Citterio, P., Kurtagic, S., Violin, M., Balotta, C., Moroni, M., Galli, M., & Monforte, A. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1328-1332.2000 · Cited by 89
HIV protease inhibitor exposure predicts cerebral small vessel disease
Soontornniyomkij, V., Umlauf, A., Chung, S. A., Cochran, M. L., Soontornniyomkij, B., Gouaux, B. D., Toperoff, W., Moore, D. J., Masliah, E., Ellis, R. J., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000262 · Cited by 89
Hresko, R. C., & Hruz, P. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025237 · Cited by 89
PAI, J.-A., Brown, M. S., & Goldstein, J. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5437 · Cited by 71
Guan, M., Fousek, K., & Chow, W. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08619.x · Cited by 67
Yan, Q., & Hruz, P. W. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000176654.97392.c7 · Cited by 65
Capel, É., Auclair, M., Caron, M., & Capeau, J. (2011) · Antiviral Therapy · doi:10.3851/imp1988 · Cited by 58
Cahn, P. E., Gatell, J. M., Squires, K., Percival, L., Piliero, P. J., Sanne, I., Shelton, S., Lazzarin, A., Odeshoo, L., Kelleher, T., et al. (2004) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/154510970400300304 · Cited by 56
Critical differences in HIV‐1 and HIV‐2 protease specificity for clinical inhibitors
Tie, Y., Wang, Y., Boross, P. I., Chiu, T., Ghosh, A. K., Tőzsér, J., Louis, J. M., Harrison, R. W., & Weber, I. T. (2012) · Protein Science · doi:10.1002/pro.2019 · Cited by 56
Self-citationHruz, P. W. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283139134 · Cited by 49
Modulation of the LDL receptor and LRP levels by HIV protease inhibitors
Tran, H., Robinson, S. E., MIKHAILENKO, I. A., & Strickland, D. K. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200487-jlr200 · Cited by 45
Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors
Ala, P. J., DeLoskey, R. J., Huston, E. E., Jadhav, P. K., Lam, P. Y. S., Eyermann, C. J., Hodge, C. N., Schadt, M. C., Lewandowski, F. A., Weber, P. C., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12325 · Cited by 43
Prabu-Jeyabalan, M., King, N. M., Nalivaika, E. A., Heilek‐Snyder, G., Cammack, N., & Schiffer, C. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1518-1521.2006 · Cited by 38
Inoue, T., Shiraki, K., Fuke, H., Yamanaka, Y., Miyashita, K., Yamaguchi, Y., Yamamoto, N., Ito, K., Sugimoto, K., & Nakano, T. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00004 · Cited by 33
Barros, S. D., Zakaroff‐Girard, A., Lafontan, M., Galitzky, J., & Bourlier, V. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111849 · Cited by 31
Hamel, F. G., Fawcett, J., Tsui, B. T., Bennett, R. G., & Duckworth, W. C. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00546.x · Cited by 27
Pepping, J. K., Otvos, L. J., Surmacz, E., Gupta, S., Keller, J. N., & Bruce‐Keller, A. J. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9529-1 · Cited by 22
Rahmouni, K., & Sigmund, C. D. (2008) · Circulation Research · doi:10.1161/circresaha.108.184366 · Cited by 21
Atazanavir: improving the HIV protease inhibitor class
Becker, S. L. (2003) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.1.3.403 · Cited by 18
de Requena, D. G., Gallego, O., de Mendoza, C., Corral, A., Jiménez‐Nácher, I., & Soriano, V. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203766774496 · Cited by 14
Hamel, F. G., Fawcett, J., Tsui, B. T., Bennett, R. G., & Duckworth, W. C. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00542.x · Cited by 4
Cited by
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Ghosh, A. K., Osswald, H. L., & Prato, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01697 · Cited by 419
Muralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1752802 · Cited by 415
Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., Hung, C.-C., Rockstroh, J. K., Girard, P.-M., Sievers, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32462-0 · Cited by 387
Llibre, J. M., Hung, C.-C., Brinson, C., Castelli, F., Girard, P.-M., Kahl, L. P., Blair, E. A., Angelis, K., Wynne, B., Vandermeulen, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33095-7 · Cited by 358
Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Mengist, H. M., Dilnessa, T., & Jin, T. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.622898 · Cited by 302
Metadata
- Authors
- Wang, Y., Lv, Z., & Chu, Y.
- Venue
- HIV/AIDS - Research and Palliative Care
- Publisher
- Informa UK Limited
- Published
- 2015-04
- Volume
- 7
- Pages
- 95
- ISSN
- 1179-1373 (ISSN-L)
- OpenAlex
- W1973395347
- Cited by
- 450
- References
- 62
- FWCI
- 17.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.